Company intelligence / Profile preview

Imvax

Philadelphia, Pennsylvania, United Statesimvax.com ↗

Ownership: Private
Employees: ~48
Development stage: Phase 2

Overview

Currently conducting a randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma. The trial is expected to be fully enrolled in the first half of 2024, with topline results timing confirmed as of January 2025[1][3].

Therapeutic areas: Oncology
Modalities: Personalizedwhole tumor-derived immunotherapies
Industry: Biotech

Drug pipeline

7 assets

IGV-001

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Imvax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imvax.

Explore the full profile